143 patents
Page 7 of 8
Utility
Materials and Methods for Treatment of Usher Syndrome Type 2A And/or Non-syndromic Autosomal Recessive Retinitis Pigmentosa (Arrp)
7 Oct 20
The present application provides materials and methods for treating a patient with one or more of Usher Syndrome Type 2A and ARRP, both ex vivo and in vivo; materials and methods for editing an USH2A gene containing a guanine deletion at nucleotide position c.2299.
Mariacarmela ALLOCCA, Akiko NOMA, Abraham SCARIA
Filed: 17 Jun 20
Utility
Compositions and Methods for Treatment of Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9)-RELATED Disorders
5 Aug 20
The present application provides materials and methods for treating a patient with one or more conditions associated with PCSK9 whether ex vivo or in vivo.
Ante Sven LUNDBERG, Samarth KULKARNI, Lawrence KLEIN, Yvonne Sarah ARATYN, Roman Lvovitch BOGORAD, Hari Kumar PADMANABHAN
Filed: 14 Feb 18
Utility
ANTI-LIV1 Immune Cell Cancer Therapy
22 Jul 20
Provided herein, in some embodiments, are methods and compositions (e.g., cell compositions) for the treatment of cancer, such as LIV1+ malignancies.
Jonathan Alexander Terrett, Jason Sagert
Filed: 6 Nov 19
Utility
Materials and Methods for Treatment of Spinocerebellar Ataxia Type 2 (SCA2) and Other Spinocerebellar Ataxia Type 2 Protein (ATXN2) Gene Related Conditions or Disorders
8 Jul 20
The present disclosure provides materials and methods for treating a patient with one or more conditions or disorders associated with ATXN2 whether ex vivo or in vivo.
Ante Sven LUNDBERG, Samarth KULKARNI, Lawrence KLEIN, Hari Kumar PADMANABHAN
Filed: 20 Feb 18
Utility
Compositions and Methods for Gene Editing
20 May 20
The present application provides materials and methods for treating a patient with one or more conditions associated with ANGPTL3 whether ex vivo or in vivo.
Ante Sven Lundberg, Samarth Kulkarni, Lawrence Klein, Hari Kumar Padmanabhan, Yvonne Sarah Aratyn
Filed: 20 Feb 18
Utility
ANTI-PTK7 Immune Cell Cancer Therapy
6 May 20
Provided herein, in some embodiments, are methods and compositions (e.g., cell compositions) for the treatment of cancer, such as PTK7+ malignancies.
Jonathan Alexander Terrett, Jason Sagert
Filed: 6 Nov 19
Utility
Materials and Methods for Treatment of Apolipoprotein C3 (Apociii)-related Disorders
22 Apr 20
The present application provides materials and methods for treating a patient with one or more conditions associated with APOCIII whether ex vivo or in vivo.
Ante Sven LUNDBERG, Lawrence KLEIN, Samarth KULKARNI, Hari Kumar PADMANABHAN
Filed: 28 Jun 17
Utility
Materials and Methods for Treatment of Merosin-deficient Cogenital Muscular Dystrophy (MDCMD) and Other Laminin, Alpha 2 (LAMA2) Gene Related Conditions or Disorders
25 Mar 20
The present application provides materials and methods for treating a patient with one or more conditions or disorders associated with LAMA2, both ex vivo or in vivo.
Ante Sven LUNDBERG, Samarth KULKARNI, Lawrence KLEIN, Hari Kumar PADMANABHAN
Filed: 13 Feb 18
Utility
Materials and Methods for Treatment of Primary Hyperoxaluria Type 1 (PH1) and Other Alanine-glyoxylate Aminotransferase (Agxt) Gene Related Conditions or Disorders
11 Mar 20
The present application provides materials and methods for treating a patient with one or more conditions or disorders associated with AGXT, both ex vivo or in vivo.
Ante Sven Lundberg, Samarth Kulkarni, Lawrence Klein, Hari Kumar Padmanabhan
Filed: 20 Feb 18
Utility
Universal Donor Cells
11 Mar 20
Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein.
Alireza Rezania
Filed: 5 Sep 19
Utility
Universal Donor Cells
11 Mar 20
Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein.
Alireza Rezania
Filed: 5 Sep 19
Utility
Methods and Compositions for Treating Cancer
26 Feb 20
Provided herein, in some embodiments, are methods and compositions (e.g., cell compositions) for the treatment of cancer.
Jonathan Alexander TERRETT, Demetrios KALAITZIDIS, Mary-Lee DEQUÉANT, Zinkal Samir PADALIA
Filed: 9 May 19
Utility
Materials and Methods for Treatment of Early Onset Parkinson's Disease (PARK1) and Other Synuclein, Alpha (Snca) Gene Related Conditions or Disorders
5 Feb 20
The present disclosure provides materials and methods for treating a patient with one or more conditions or disorders associated with SNCA whether ex vivo or in vivo.
Ante Sven LUNDBERG, Samarth KULKARNI, Lawrence KLEIN, Hari Kumar PADMANABHAN
Filed: 15 Feb 18
Utility
Compositions and Methods for Genomic Editing by Insertion of Donor Polynucleotides
5 Feb 20
The present disclosure provides donor polynucleotides, genome editing systems, methods, and kits which correct or induce a mutation in a gDNA.
Troy Dean CARLO, Roman Lvovitch BOGORAD
Filed: 27 Jun 19
Utility
Materials and Methods for Treatment of Glycogen Storage Disease Type 1A
18 Dec 19
The present application provides materials and methods for treating a patient with Glycogen Storage Disease type la (GSD1a) both ex vivo and in vivo.
Chad Albert COWAN, Roman Lvovitch BOGORAD, Ante Sven LUNDBERG, Kirsten Leah BEAUDRY
Filed: 6 Nov 16
Utility
Materials and Methods for Treatment of Duchenne Muscular Dystrophy
11 Dec 19
The present application provides materials and methods for treating a patient with Duchenne Muscular Dystrophy (DMD) both ex vivo and in vivo.
Ami Meda KABADI, Chad Albert COWAN, Ante Sven LUNDBERG
Filed: 27 Oct 16
Utility
Materials and Methods for Treatment of Dystrophic Epidermolysis Bullosa (Deb) and Other Collagen Type VII Alpha 1 Chain (COL7A1) Gene Related Conditions or Disorders
4 Dec 19
The present disclosure provides materials and methods for treating a patient with one or more conditions or disorders associated with COL7A1 whether ex vivo or in vivo.
Ante Sven LUNDBERG, Samarth KULKARNI, Lawrence KLEIN, Hari Kumar PADMANABHAN
Filed: 13 Feb 18
Utility
Materials and Methods for Engineering Cells and Uses Thereof In Immuno-oncology
4 Dec 19
Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
Jonathan Alexander Terrett, Demetrios Kalaitzidis, Lawrence Klein
Filed: 3 Jun 19
Utility
Materials and Methods for Engineering Cells and Uses Thereof In Immuno-oncology
4 Dec 19
Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
Jonathan Alexander Terrett, Demetrios Kalaitzidis, Lawrence Klein
Filed: 5 Jun 19
Utility
Methods and Compositions for Efficient Gene Deletion
27 Nov 19
Provided herein are gene-editing methods and compositions for improving the efficiency of deleting segments of DNA from cells, cells that are genetically modified using the disclosed methods and compositions, and methods of treatment using the genetically modified cells.
ELIZABETH PAIK, MAURICIO CORTES
Filed: 23 May 19